Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.

Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, Raskind MA, Peskind ER.

Am J Geriatr Psychiatry. 2009 Sep;17(9):744-51. doi: 10.1097/JGP.0b013e3181ab8c61.

2.

Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Santamato A, Lozupone M, Prete C, Greco A, Pilotto A, Logroscino G.

Expert Opin Pharmacother. 2015;16(17):2581-8. doi: 10.1517/14656566.2015.1092520. Epub 2015 Sep 21. Review.

PMID:
26389682
3.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
4.

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Liu CS, Chau SA, Ruthirakuhan M, Lanctôt KL, Herrmann N.

CNS Drugs. 2015 Aug;29(8):615-23. doi: 10.1007/s40263-015-0270-y. Review.

PMID:
26271310
5.

Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.

Liu CS, Ruthirakuhan M, Chau SA, Herrmann N, Carvalho AF, Lanctôt KL.

Curr Alzheimer Res. 2016;13(10):1134-44. Review.

PMID:
27137221
6.

An update on the advancements in the treatment of agitation in Alzheimer's disease.

Porsteinsson AP, Antonsdottir IM.

Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28. Review.

PMID:
28300462
7.

Biologic markers and neurochemical correlates of agitation and psychosis in dementia.

Kirby M, Lawlor BA.

J Geriatr Psychiatry Neurol. 1995 Oct;8 Suppl 1:S2-7. Review.

PMID:
8561841
8.

Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.

Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG, Peskind E, Porsteinsson AP, Reich E, Sampaio C, Steffens D, Wortmann M, Zhong K; International Psychogeriatric Association.

Int Psychogeriatr. 2015 Jan;27(1):7-17. doi: 10.1017/S1041610214001963. Epub 2014 Oct 14.

9.

AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.

Garay RP, Grossberg GT.

Expert Opin Investig Drugs. 2017 Jan;26(1):121-132. doi: 10.1080/13543784.2017.1267726. Epub 2016 Dec 11. Review.

PMID:
27936965
10.

Need to Recalibrate Research Outcomes in Alzheimer's Disease: Focus on Neuropsychiatric Symptoms.

Canevelli M, Cesari M, Lucchini F, Valletta M, Sabino M, Lacorte E, Vanacore N, Bruno G.

J Am Geriatr Soc. 2017 Sep;65(9):2071-2073. doi: 10.1111/jgs.14989. Epub 2017 Jul 6. Review.

PMID:
28682462

Supplemental Content

Support Center